Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 6

The Rationale for PARP Inhibition plus IO in Ovarian Cancer

, , ,

Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Recent Updates in PARP Inhibitor Indications for Ovarian Cancer
    EP. 2: PARP Inhibitors in Ovarian Cancer: The SOLO-3 Trial
    EP. 3: PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer
    EP. 4: Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial
    EP. 5: Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial
    Now Viewing
    EP. 6: The Rationale for PARP Inhibition plus IO in Ovarian Cancer
    EP. 7: Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment
    EP. 8: PARP Inhibitor Resistance in Ovarian Cancer Treatment
    EP. 9: The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer
    EP. 10: Antibody-Drug Conjugates in Ovarian Cancer Treatment
    EP. 11: Clinical Trial Data on Antibody-Drug Conjugate Treatment for Ovarian Cancer
    EP. 12: Investigative Therapies in Recurrent Ovarian Cancer
    EP. 13: Treatment of Rare Tumors in Ovarian Cancer
    EP. 14: Key Data Highlights in Ovarian Cancer
    x